NPDUIS Analytical Studies


National Prescription Drug Utilization Information System (NPDUIS) publishes a variety of studies that provide Canadians with comprehensive information on drug pricing, utilization, and cost trends in Canada and internationally. These include Annual Publications, Report Series, Focused Research Reports, and Presentations.

Annual Publications

CompassRx: Annual Public Drug Plan Expenditure Report

NPDUIS CompassRx, 4th Edition

2017/18 Edition 
Published: September 2019 | PDF 2.25 MB

Previous Editions

CompassRx,2016/17
Published: September 2018 | PDF 2.80 MB

CompassRx, 2015/16
Published: May 2017 | PDF 2.26 MB

CompassRx, 2013/14
Published: May 2016 | PDF 4.02 MB

CompassRx, 2012/13
Published: March 2015 | PDF 4.37 MB

Analysis Brief: CompassRx, 2012/13
Published: March 2015 | PDF 804 kb


Meds Entry Watch

Meds Entry Watch

Previous Editions

2017 Edition
Published: February 2019 | PDF 3.35 MB

2016 Edition
Published: June 2018 | PDF 758 kb

2015 Edition
Published: April 2017 | PDF 2.33 MB


Meds Pipeline Monitor

Meds Pipeline Monitor

2019 Edition New
Published: April 2020 | PDF 2.4 MB

Previous Reports

2018 Edition
Published: May 2019 | PDF 1.94 MB

New Drug Pipeline Monitor, 7th Edition
Published: December 2015 | PDF 1.43 MB

New Drug Pipeline Monitor, 6th Edition
Published: December 2014 | PDF 723 kb

New Drug Pipeline Monitor, 5th Edition
Published: December 2013

New Drug Pipeline Monitor, 4th Edition
Published: April 2013

New Drug Pipeline Monitor, 3rd Edition
Published: July 2011

New Drug Pipeline Monitor, 2nd Edition
Published: July 2008

New Drug Pipeline Monitor, 1st Edition
Published: June 2007

Report Series

Formularies in Canada

Formularies in Canada

Part 1: General Overview
Published: October 2017 | PDF 2.07 MB

List of Selected Drugs
Published: October 2017 | PDF 1 MB


Market Intelligence Report

Market Intelligence Report

Combination Inhalers for Asthma, 2018 New
Published: April 2020 | PDF 4 MB

Previous Reports

Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Drugs for Retinal Conditions, 2017
Published: December 2018 | PDF 1 MB

Biologic Response Modifier Agents, 2015 - Supplement: 2017
Published: September 2018 | PDF 875 KB

Biologic Response Modifier Agents, 2015
Published: October 2016 | PDF 2.71 MB


Generics360: Generic Drugs in Canada

Generic360

2018 Edition
Published: August 2019 | PDF 1.10 MB

Previous Reports

Generics360: Generic Drugs in Canada - 2016 Edition
Published: February 2018 | PDF 1.19 MB

Generics360: Generic Drugs in Canada - 2014 Edition
Published: February 2016 | PDF 1.76 MB

Generic Drugs in Canada, 2013
Published: December 2014 | PDF 645 kb

Analysis Brief: Generic Drugs in Canada, 2013
Published: December 2014 | PDF 182 kb

Analytical Snapshot: International Generic Price Comparison, Early 2011
Published: August 2013 | PDF 899 kb

Generic Drugs in Canada: International Price Comparisons and Potential Cost Savings
Published: September 2011 | PDF 368 kb

Generic Drugs in Canada: Market Structure – Trends and Impacts
Published: December 2010 | PDF 310 kb

Generic Drugs in Canada: Price Trends and International Price Comparisons, 2007
Published: December 2010 | PDF 415 kb


Private Drug Plans in Canada

Private Drug Plans in Canada - Part 1: Generic Market 2005–2013

Part 1: Generic Market 2005–2013
Published: December 2015 | PDF 3.02 MB

Focused Reports
Poster Presentations

Poster Presentations

Previous Posters

2018 Conference Posters:

The New Drug Landscape: International Availability and Pricing | PDF 375 kb

Generic Drugs in Canada, 2016 | PDF 407 kb

Cost Drivers of Public Drug Plans in Canada, 2016/17 | PDF 406 kb

Private Drug Plans in Canada: High-Cost Drugs and Beneficiaries, 2005 to 2017 | PDF 556 kb

The Cost of Drugs for Age-related Macular Degeneration in Canada and Internationally | PDF 821 kb

The Cost of New Oral Anti-diabetic Drugs in Canada and Internationally | PDF 2.29 MB

Cost Drivers of Private Drug Plans in Canada, 2017 | PDF 755 kb

2017 Conference Posters:

The Canadian Market for Biologic Response Modifier Agents, 2015 | PDF 305 kb

Generic Drugs in Canada, 2015 | PDF 369 kb

A Review of Public Coverage of CDR Reviewed Drugs | PDF 354 kb

A Review of Public and Private Coverage of iJODR/pCODR Reviewed Drugs | PDF 325 kb

Potential Savings from Biosimilars in Canada | PDF 440 kb

2016 Conference Posters:

Orphan Drug Launch Monitor (ODLM) | PDF 324 kb

Cost Pressures in the Canadian Hospital Drug Market, 2006–2014 | PDF 373 kb

The Use of Diabetes Drugs in Canadian Public Drug Plans | PDF 369 kb

Private Drug Plans in Canada: Cost Drivers, 2008 to 2015 | PDF 400 kb

New Drug Launch Monitor, 2009-2015 | PDF 373 kb

Cost Pressure of the New Hepatitis C Drugs in Canada | PDF 310 kb

Private Drug Plans in Canada: High-Cost Drugs and Beneficiaries, 2005 to 2015 | PDF 296 kb

2015 Conference Posters:

Generic Drugs in Canada, 2013 | PDF 373 kb

Cost Drivers of Private Drug Plans in Canada, 2012/13 | PDF 400 kb

Cost Drivers of Public Drug Plans in Canada, 2012/13 | PDF 1021 kb

The Use of Gabapentin in Public Drug Plans | PDF 1480 kb

Monitoring New Drugs in Canada: A Multifaceted Approach | PDF 326 kb

Generic Drugs in Canadian Private Plans, 2005–2013 | PDF 338 kb

2014 Conference Posters:

Private Drug Plans in Canada PDF 695 kb

New Drug Pipeline Monitor PDF 378 kb

Slide Presentations

biosimilar

Potential Savings from Biosimilars in Canada
Published: March 2017 | PDF 1.56 MB

Slide Presentations

Resources

Reference Documents

These documents provide background material to supplement the NPDUIS analytical studies:

Canadian Public Drug Plan Designs and Policies

Methods

General Information

Budget Impact Analysis Guidelines

Budget Impact Analysis Guidelines

Date modified: